MiNK Therapeutics, Inc. announced on July 11, 2025, the publication of a landmark case in Nature’s Oncogene, detailing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer. The patient achieved this remission following treatment with agenT-797, MiNK’s allogeneic iNKT cell therapy, in combination with nivolumab.
The patient had progressed through multiple prior lines of therapy, including platinum-based chemotherapy, autologous stem cell transplantation, radiation, and checkpoint regimens. Following a single infusion of agenT-797, the patient achieved a complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later.
The treatment was well-tolerated, with no cytokine release syndrome (CRS) or graft-versus-host disease (GvHD) observed. This publication adds to the growing body of clinical evidence supporting the potential of agenT-797 in solid tumors and highlights the unique biology of iNKT cells to overcome resistance to immune checkpoint inhibitors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.